Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR -mutant non-small-cell lung cancer. We determined the prognostic impact and association...

Full description

Bibliographic Details
Main Authors:	Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-01-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231222604

Similar Items

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
by: Jia-Shiuan Ju, et al.
Published: (2023-11-01)

The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
by: Tzu-Hsuan Chiu, et al.
Published: (2022-03-01)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
by: John Wen-Cheng Chang, et al.
Published: (2022-02-01)

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
by: Jiameng Lu, et al.
Published: (2024-01-01)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
by: Motohiro Tamiya, et al.
Published: (2021-05-01)

Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
by: Zhijie Wang, et al.
Published: (2014-01-01)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
by: Chen‐Te Wu, et al.
Published: (2023-09-01)

Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines
by: Jing LI, et al.
Published: (2015-08-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
by: Weiting Li, et al.
Published: (2022-07-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

TKI Resistance for T790M Mutation
by: Hong WANG, et al.
Published: (2015-04-01)

The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
by: Wen-Chien Cheng, et al.
Published: (2022-12-01)

Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
by: Chun-Ta Huang, et al.
Published: (2023-03-01)

Targeting HER3 to overcome EGFR TKI resistance in NSCLC
by: Qiuqiang Chen, et al.
Published: (2024-01-01)

The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
by: Baohui HAN, et al.
Published: (2009-12-01)

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, et al.
Published: (2022-09-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
by: Eveline Van De Stadt, et al.
Published: (2022-10-01)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01)

Treatment of Advanced NSCLC with Unknown EGFR Gene Status __ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
by: Kenichi Koyama, et al.
Published: (2022-04-01)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
by: Min Yu, et al.
Published: (2022-06-01)

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
by: Hideharu Kimura, et al.
Published: (2019-11-01)

EGFR‐TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR‐TKI–associated interstitial lung disease in Asian
by: Tai‐Huang Lee, et al.
Published: (2022-11-01)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
by: Li Sun, et al.
Published: (2021-01-01)

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
by: Luwei Han, et al.
Published: (2021-04-01)

Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation
by: Chih-Hsi Scott Kuo, et al.
Published: (2022-01-01)

Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC
by: Jennifer Novak, et al.
Published: (2022-08-01)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
by: John Wen‐Cheng Chang, et al.
Published: (2022-07-01)

Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2022-10-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
by: Bin Zou, et al.
Published: (2017-07-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
by: Rajeswara Rao Arasada, et al.
Published: (2018-08-01)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis
by: Wenxian Wang, et al.
Published: (2018-10-01)

A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
by: Bing Han, et al.
Published: (2023-11-01)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021-05-01)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
by: Yen-Hsiang Huang, et al.
Published: (2021-06-01)